19.70
0.00
(0.00%)
As of January 15 at 2:08:29 PM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
180,578.00
180,578.00
193,460.00
182,570.00
178,906.00
Cost of Revenue
99,857.00
99,857.00
110,016.00
96,464.00
92,982.00
Gross Profit
80,721.00
80,721.00
83,444.00
86,106.00
85,924.00
Operating Expense
56,559.00
56,559.00
56,378.00
59,665.00
57,341.00
Operating Income
24,162.00
24,162.00
27,066.00
26,441.00
28,583.00
Net Non Operating Interest Income Expense
2,769.00
2,769.00
1,817.00
1,281.00
1,678.00
Pretax Income
27,299.00
27,299.00
30,419.00
28,059.00
29,826.00
Tax Provision
4,507.00
4,507.00
5,805.00
4,924.00
4,433.00
Net Income Common Stockholders
22,792.00
22,792.00
24,614.00
23,135.00
25,393.00
Diluted NI Available to Com Stockholders
22,792.00
22,792.00
24,614.00
23,135.00
25,393.00
Basic EPS
1.48
--
1.60
1.50
1.65
Diluted EPS
1.47
--
1.60
1.50
1.64
Basic Average Shares
15,400.00
--
15,383.75
15,400.00
15,400.00
Diluted Average Shares
15,458.00
--
15,383.75
15,455.00
15,453.00
Total Expenses
156,416.00
156,416.00
166,394.00
156,129.00
150,323.00
Net Income from Continuing & Discontinued Operation
22,792.00
22,792.00
24,614.00
23,135.00
25,393.00
Normalized Income
22,792.00
22,792.00
24,614.00
23,135.00
25,393.00
Interest Income
3,094.00
3,094.00
1,875.00
1,379.00
1,845.00
Interest Expense
325.00
325.00
58.00
98.00
167.00
Net Interest Income
2,769.00
2,769.00
1,817.00
1,281.00
1,678.00
EBIT
27,624.00
27,624.00
30,477.00
28,157.00
29,993.00
EBITDA
34,838.00
34,838.00
36,788.00
36,958.00
39,885.00
Reconciled Cost of Revenue
99,857.00
99,857.00
110,016.00
96,464.00
92,982.00
Reconciled Depreciation
7,214.00
7,214.00
6,311.00
8,801.00
9,892.00
Net Income from Continuing Operation Net Minority Interest
22,792.00
22,792.00
24,614.00
23,135.00
25,393.00
Normalized EBITDA
34,838.00
34,838.00
36,788.00
36,958.00
39,885.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 9/25/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4197.TWO Visgeneer Inc.
9.78
0.00%
7607.TWO DuoGenic StemCells corporation
20.20
-3.81%
6652.TWO Eusol Biotech Co.,Ltd.
7.49
-4.07%
6879.TWO TCI GENE Inc.
52.00
0.00%
4170.TWO VBI
13.80
-1.43%
6827.TWO MegaPro Biomedical Co., Ltd
14.45
+2.48%
6709.TWO Advagene Biopharma Co., Ltd.
20.20
0.00%
6999.TWO Han Biomedical
36.00
+3.75%
7754.TWO AnnJi
32.70
-3.25%
7725.TWO LabTurbo Biotech Corporation
24.00
0.00%